• Explore /
  • Poster
  • / Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).

Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).

Abstract Poster

Authors

null

Markus H. Moehler

University Medical Center Mainz, Mainz, Germany

Markus H. Moehler , Peter C. Thuss-Patience , Baruch Brenner , Federico Longo , Johannes Meiler , Thomas Jens Ettrich , Ralf Hofheinz , Salah-Eddin Al-Batran , Arndt Vogel , Lothar Mueller , Manfred P. Lutz , Kersten Borchert , Richard Greil , Maria Alsina , Aysun Karatas , Eric Van Cutsem , Ralph Keller , Julian Larcher-Senn , Sylvie Lorenzen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT1627379

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4011)

DOI

10.1200/JCO.2017.35.15_suppl.4011

Abstract #

4011

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Markus Hermann Moehler

First Author: Jong-Mu Sun

First Author: Yelena Yuriy Janjigian

First Author: Samuel J Klempner